,i #aahth ,,congress #ast ,session ,h4 ,r4 #cbhb ,,in ,,the ,,house ,,of ,,representatives ,may #ae1 #bjbc,mrs4 ,harshbarger 7for herself1 ,ms4 ,schrier1 ,mr4 ,bilirakis1 and ,ms4 ,schakowsky7 introduced the following bill2 which was referred to the ,committee on ,ways and ,means1 and in addition to the ,committee on ,energy and ,commerce1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend title ,,xviii of the ,social ,security ,act to promote transparency of common ownership interests under parts ,c and ,d of the ,medicare program4 #a4 ,short title ,this ,act may be cited as the ,promoting ,transparency and ,healthy ,competition in ,medicare ,act4 #b4 ,promoting transparency of common ownership interests under parts ,c and ,d of the ,medicare program 7a7 ,medicare ,advantage ,section #aheg7;e7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#bg7;e77 is amended by adding at the end the following new paragraph3 7#f7 ,required disclosure of certain information relating to health care provider ownership 7,a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a contract under this section with an ,,ma organization shall require the organization to report to the ,secretary1 not later than #a year after the last day of such plan year1 the information described in subparagraph 7,b7 with respect to such plan year4 7,b7 ,information described ,for purposes of subparagraph 7,a71 the information described in this subparagraph is1 with respect to an ,,ma organization and a plan year1 the following3 7i7 ,the number of items and services furnished during such plan year by each specified provider 7as defined in subparagraph 7,c77 for which payment was made by such organization4 7ii7 ,the number of items and services furnished during such plan year by providers of services or suppliers not described in clause 7i7 for which payment was made by such organization4 7iii7 ,the average per-enrollee number of qualifying diagnoses 7as defined in subparagraph 7,c77 made during such plan year by specified providers 7including through chart reviews and health risk assessments7 with respect to individuals enrolled under an ,,ma plan offered by such organization1 broken down by site of service of such providers1 as specified by the ,secretary4 7iv7 ,the average per-enrollee number of qualifying diagnoses made during such plan year by providers of services and suppliers not described in clause 7iii7 7including through such reviews and assessments7 with respect to such individuals1 broken down by site of service of such providers4 7v7 ,the average risk score 7as calculated under the methodology described in subparagraph 7,c77i77 for such an individual for such plan year who received items and services from a specified provider during such plan year4 7vi7 ,the average risk score for such an individual for such plan year who did not receive items and services from a specified provider during such plan year4 7vii7 ,the average risk score for such an individual for such plan year who received a health risk assessment from an assessment entity that was a specified assessment entity during such plan year4 7viii7 ,the average risk score for such an individual for such plan year who received a health risk assessment from an assessment entity that was not a specified assessment entity during such plan year4 7ix7 ,the number of prior authorization requests for an item or service submitted to such organization during such plan year1 the number of such requests that were approved1 the number of such requests that were denied1 and the number of such denied requests that were subsequently appealed and then approved1 broken down by whether the entity proposing to furnish such item or service was a specified provider or not a specified provider4 7x7 ,the total amount of incentive-based payments made to1 and the total amount of shared losses recoupments collected from1 specified providers during such plan year4 7xi7 ,the total amount of incentive-based payments made to1 and the total amount of shared losses recoupments collected from1 providers of services and suppliers not described in clause 7x7 during such plan year4 7xii7 ,for each ,,ma plan offered by such organization during such plan year-- 7,i7 the total amount of payments made under section #ahec7;a77#a7 to such organization for coverage of individuals under such plan1 and the total amount of payments made by such individuals to such organization for coverage under such plan2 7,,ii7 the total amount expended under such plan as payment for items and services furnished by each specified provider during such year2 7,,iii7 the total amount expended under such plan as payment for items and services furnished by providers of services or suppliers not described in subclause 7,,ii7 during such year2 7,,iv7 the medical loss ratio under such plan with respect to individuals furnished an item or service from a specified provider during such year2 and 7,v7 the medical loss ratio under such plan with respect to individuals not described in subclause 7,,iv74 7,c7 ,definitions ,in this paragraph3 7i7 ,assessment entity ,the term assessment entity means an entity with a focus on furnishing in-home medical assessments1 as specified by the ,secretary4 7ii7 ,qualifying diagnosis ,the term qualifying diagnosis means1 with respect to an individual1 a diagnosis that is taken into account in calculating a risk score for such individual under the risk adjustment methodology established by the ,secretary pursuant to section #ahec7;a77#c74 7iii7 ,specified assessment entity ,the term specified assessment entity means1 with respect to an ,,ma organization and a plan year1 an assessment entity with respect to which such organization 7or any person with an ownership or control interest 7as defined in section #aabd7;a77#c77 in such organization7 is a person with an ownership or control interest 7as so defined74 7iv7 ,specified provider ,the term specified provider means1 with respect to an ,,ma organization and a plan year1 a provider of services or supplier with respect to which such organization 7or any person with an ownership or control interest 7as defined in section #aabd7;a77#c77 in such organization7 is a person with an ownership or control interest 7as so defined74 7,d7 ,nonapplication of ,paperwork ,reduction ,act ,chapter #ce of title #dd1 ,united ,states ,code1 shall not apply to information collected under this paragraph4 4 7b7 ,pharmacy benefit manager and pharmacy information ,section #ahfj;,d-#ab7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aab7;b77 is amended by adding at the end the following new paragraphs3 7#i7 ,provision of information relating to pharmacy ownership 7,a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a contract entered into under this part with a ,,pdp sponsor shall require the sponsor to report to the ,secretary1 not later than #a year after the last day of such plan year1 the information described in subparagraph 7,b7 with respect to such plan year4 7,b7 ,information described ,for purposes of subparagraph 7,a71 the information described in this subparagraph is1 for each prescription drug plan offered by a ,,pdp sponsor for a plan year1 the following3 7i7 ,the negotiated price for each covered part ,d drug for which benefits are available under such plan for each network pharmacy 7including an identification of whether each such pharmacy is a specified pharmacy74 7ii7 ,the average per-drug amount of direct and indirect remuneration paid by specified pharmacies for such covered part ,d drugs dispensed during such plan year under such plan4 7iii7 ,the average per-drug amount of direct and indirect remuneration paid by pharmacies not described in clause 7ii7 for such covered part ,d drugs dispensed during such plan year under such plan4 7,c7 ,definitions ,in this paragraph3 7i7 ,direct and indirect remuneration ,the term direct and indirect remuneration has the meaning given such term in section #dbc4cjh of title #db1 ,code of ,federal ,regulations 7or any successor regulation74 7ii7 ,network pharmacy ,the term network pharmacy has the meaning given such term in section #dbc4ajj of title #db1 ,code of ,federal ,regulations 7or any successor regulation74 7iii7 ,negotiated price ,the negotiated price for a covered part ,d drug shall take into account all negotiated price concessions1 such as discounts1 direct or indirect subsidies1 rebates1 and direct or indirect remunerations1 for such drug1 and include any dispensing fee for such drug4 7iv7 ,specified pharmacy ,the term specified pharmacy means1 with respect to an ,,pdp sponsor and a plan year1 a pharmacy with respect to which such sponsor 7or any person with an ownership or control interest 7as defined in section #aabd7;a77#c77 in such sponsor7 is a person with an ownership or control interest 7as so defined74 7,d7 ,nonapplication of ,paperwork ,reduction ,act ,chapter #ce of title #dd1 ,united ,states ,code1 shall not apply to information collected under this paragraph4 7#aj7 ,provision of information by pharmacy benefit managers 7,a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a contract entered into under this part with a ,,pdp sponsor shall prohibit such sponsor from entering into a contract with a specified pharmacy benefit manager for purposes of performing any service with respect to covered part ,d drugs dispensed under any prescription drug plan offered by such sponsor for such plan year unless such manager agrees to report to the ,secretary1 not later than #a year after the last day of such plan year1 the information described in subparagraph 7,b7 with respect to each prescription drug plan for which such manager is providing any such service during such plan year1 regardless of the sponsor of such plan4 7,b7 ,information described ,for purposes of subparagraph 7,a71 the information described in this subparagraph is1 with respect to a pharmacy benefit manager performing services under a prescription drug plan for a plan year1 the following3 7i7 ,with respect to the total amount of pharmacy and manufacturer rebates collected by such manager 7or collected on behalf of such plan by any other entity with a contract in effect with such manager for such collection7 for all covered part ,d drugs dispensed under such plan during such plan year-- 7,i7 the total amount of such rebates passed through to the ,,pdp sponsor of such plan2 and 7,,ii7 the total amount of such rebates retained by such manager or such other entities4 7ii7 ,the total amount paid by such manager to pharmacies for drugs furnished under such plan during such plan year4 7iii7 ,the total amount of payments made by such sponsor to such manager as reimbursement for such manager's payments described in clause 7ii74 7iv7 ,the total amount of payments made by such sponsor to such manager as fees for services furnished by such manager with respect to such plan for such plan year 7not including payments described in clause 7iii774 7v7 ,the total amount of administrative costs incurred by such manager for furnishing such services under such plan for such plan year4 7vi7 ,a specification as to whether such manager is a specified pharmacy benefit manager with respect to the ,,pdp sponsor of such plan4 7,c7 ,definition ,in this paragraph1 the term specified pharmacy benefit manager means1 with respect to an ,,pdp sponsor and a plan year1 a pharmacy benefit manager with respect to which such sponsor 7or any person with an ownership or control interest 7as defined in section #aabd7;a77#c77 in such sponsor7 is a person with an ownership or control interest 7as so defined74 4 7c7 ,publication ,not later than ,january #a1 #bjbg1 the ,secretary of ,health and ,human ,services shall establish a process under which information submitted to the ,secretary pursuant to the amendments made by this section is publicly disclosed4 ,such process shall ensure that any information so disclosed does not identify a specific drug manufacturer1 provider of services or supplier1 pharmacy1 pharmacy benefit manager1 or any price charged with respect to a particular drug4